Amgen drug combined with immunotherapy extends survival in lung cancer trial

4

* Imdelltra patients lived median of 21.7 months vs 12.1 months for control group * Nearly 80% of Imdelltra patients alive after one year * About 21% of Imdelltra patients had serious side effects vs

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)